Proteostasis Therapeutics
Cambridge
About Proteostasis Therapeutics
Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $179.3M
- Funding stage: M&A
- Last round: Post-IPO Equity (Oct 2018)
- Ticker: nasdaq:PTI
- Website: proteostasis.com
- Phone: 6172257801
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/proteostasis-therapeutics-202964 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.